| Literature DB >> 22244654 |
Michael K Mwaniki1, Maurine Atieno, Joy E Lawn, Charles R J C Newton.
Abstract
BACKGROUND: Neonatal interventions are largely focused on reduction of mortality and progression towards Millennium Development Goal 4 (child survival). However, little is known about the global burden of long-term consequences of intrauterine and neonatal insults. We did a systematic review to estimate risks of long-term neurocognitive and other sequelae after intrauterine and neonatal insults, especially in low-income and middle-income countries.Entities:
Mesh:
Year: 2012 PMID: 22244654 PMCID: PMC3273721 DOI: 10.1016/S0140-6736(11)61577-8
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321
Grading of severity of impairment across multiple domains
| Cognition | Cognitive | Cognitive | |
| Motor | Difficulty in everyday motor activities appropriate for age but able to move around without help | Difficulty in holding implements, dressing, and sitting upright. Able to move around with help | Inability to walk and absence of functional use of hands |
| Hearing | Audiometric hearing threshold level of 26–30 dB HL in children aged <15 years and 26–40 dB HL in adults | Audiometric hearing threshold level of 31–60 dB HL in children aged <15 years and 41–60 dB HL in adults. Hearing aid not normally used. Or, audiometric hearing threshold level of 31–60 dB HL in children aged <15 years and 41–60 dB HL in adults. Hearing aid normally used | Audiometric hearing threshold level of 61 dB HL or greater. Hearing aid not normally used. Or, audiometric hearing threshold level of 61 dB HL or greater. Hearing aid normally used |
| Vision | Visual acuity in the best eye of <6/12 but ≥6/18, or corresponding visual field loss | Visual acuity in the best eye of <6/18 but ≥6/60; or, corresponding visual field loss | Visual acuity in the best eye of <6/60 but >3/60; or, visual field loss with blindness (visual acuity in the best eye of <3/60); or, corresponding visual field loss |
| Seizure disorder | More than one non-febrile seizure per year | More than one non-febrile seizure per month | More than one non-febrile seizure per week |
| Behavioural | Any reported | .. | .. |
| Multidomain | One or two domains mildly affected | Three or more domains mildly affected, or one moderately affected and more than one mildly affected | If any domain is severely affected, or two or more are moderately affected |
HL=hearing level.
Definitions of behavioural problems could not be standardised or assessed.
Figure 1Literature review
*Six studies included data for more than one insult.
Summary of sequelae risk after intrauterine and neonatal insults
| Cognition, general developmental delay, or learning difficulties | Cerebral palsy | Deaf or hearing loss | Impaired vision or blind | Gross motor and coordination | Epilepsy | Behavioural problems | |||
|---|---|---|---|---|---|---|---|---|---|
| Sepsis (5 studies) | 2442 | 977 (40%) | 720 (74%) | 353 (36%) | 97 (10%) | 317 (32%) | 5 (1%) | .. | .. |
| Meningitis (11 studies) | 501 | 209 (42%) | 209 (100%) | 43 (21%) | 25 (12%) | 84 (40%) | 10 (5%) | 24 (11%) | 3 (1%) |
| Hypoxic ischaemic encephalopathy (27 studies) | 2708 | 1002 (37%) | 453 (45%) | 291 (29%) | 95 (9%) | 258 (26%) | 167 (17%) | 122 (12%) | 15 (1%) |
| Preterm birth (47 studies) | 6558 | 2006 (31%) | 1209 (60%) | 539 (27%) | 148 (7%) | 224 (11%) | 202 (10%) | 20 (1%) | 25 (1%) |
| Jaundice (20 studies) | 7212 | 1311 (18%) | 985 (75%) | 190 (14%) | 146 (11%) | .. | 36 (3%) | 40 (3%) | 57 (4%) |
| Tetanus (4 studies) | 109 | 28 (26%) | 28 (100%) | 1 (4%) | .. | .. | 4 (14%) | .. | 6 (21%) |
| Cytomegalovirus (17 studies) | 918 | 377 (41%) | 250 (66%) | 23 (6%) | 251 (67%) | 13 (3%) | 60 (16%) | 23 (6%) | 7 (2%) |
| Herpes (9 studies) | 311 | 116 (37%) | 109 (94%) | 32 (28%) | 2 (2%) | 55 (47%) | 34 (29%) | 27 (23%) | 2 (2%) |
| Rubella (6 studies) | 890 | 720 (81%) | 42 (6%) | .. | 576 (80%) | 191 (27%) | 44 (6%) | .. | 2 (<1%) |
| Toxoplasmosis (5 studies) | 512 | 105 (21%) | 27 (26%) | .. | .. | 86 (82%) | 1 (1%) | 12 (11%) | .. |
| Syphilis (0 studies) | .. | .. | .. | .. | .. | .. | .. | .. | .. |
| Overall | 22 161 | 6851 (31%) | 4032 (59%) | 1472 (21%) | 1340 (20%) | 1228 (18%) | 563 (8%) | 268 (4%) | 117 (2%) |
Impairment by sequelae type greater than 100% because of overlap.
Cerebral palsy was not defined and classified but motor and coordination impairments were reported.
The risk of impairment sequelae by insult and overall
| At least one sequela in any domain | 39·4% (20·0–54·8) | 48·9% (39·1–59·2) | 46·4% (36·9–68·4) | 44·2% (20·6–53·9) | 27·9% (18·6–46·4) | 25·3% (13·2–39·2) | 20·8% (11·5–45·0) | 48·3% (20·8–73·8) | 51·5% (31·3–56·5) | 82·0% (68·5–100·0) | 55·6% (51·2–85·7) |
| Cognitive or learning difficulties or developmental delay | 26·0% (14·3–43·4) | 30·0% (26·4–44·4) | 33·3% (26·7–36·8) | 29·7% (13·0–40·7) | 20·9% (12·5–39·5) | 16·1% (11·7–23·9) | 20·8% (10·5–95·8) | 27·8% (9·5–57·1) | 12·5% (5·2–17·4) | 22·7% (7·1–23·6) | 33·3% (19·1–70·8) |
| Cerebral palsy | 15·5% (9·2–28·6) | 12·4% (11·1–14·9) | 11·7% (6·2–29·0) | 28·3% (19·1–42·0) | 11·6% (8·0–17·7) | 10·5% (3·7–14·4) | .. | 24·3% (11·4–35·8) | 29·9% (20·0–39·1) | .. | .. |
| Hearing loss | 13·4% (5·0–28·6) | 18·7% (8·9–36·1) | 8·6% (2·6–13·1) | 10·0% (5·0–11·6) | 2·9% (1·2–8·7) | 11·1% (5·7–23·0) | .. | 25·0% (16·1–50·0) | .. | 56·9% (28·6–69·9) | .. |
| Visual disturbance | 12·9% (3·5–33·4) | 12·5% (11·1–21·9) | 20·0% (13·3–36·8) | 12·0% (3·3–24·3) | 2·8% (1·4–11·3) | .. | .. | 7·1% (2·3–21·8) | 48·7% (40·8–57·2) | 37·3% (31·3–65·2) | 55·6% (51·2–85·7) |
| Epilepsy | 14·7% (7·2–44·4) | .. | 15·8% (5·4–50·0) | 10·9% (3·4–23·1) | 31·3% (29·4–33·3) | 11·9% (3·5–16·7) | .. | 11·1% (10·7–21·7) | 32·5% (30·2–36·1) | .. | 14·3% (11·1–16·7) |
| Gross motor and coordination problems | 16·9% (10·0–29·2) | .. | 6·7% (2·6–10·6) | 20·1% (5·6–33·3) | 18·9% (11·8–25·6) | 20·1% (12·8–39·4) | .. | 10·9% (2·2–58·2) | 25·0% (22·2–37·5) | .. | 6·6% (4·8–8·3) |
| Behavioural problems | 10·7% (5·5–25·0) | .. | .. | 13·1% (2·9–23·3) | 9·4% (4·9–17·9) | .. | .. | .. | .. | .. | .. |
| Severe sequela in at least one domain | 18·5% (7·7–33·3) | 39·9% (32·1–44·8) | 15·0% (10·8–26·3) | 27·1% (20·6–38·5) | 9·6% (6·6–18·2) | 9·3% (2·3–22·7) | .. | 11·1% (5·6–27·3) | 34·8% (25·0–40·6) | 82·3% (63·6–96·1) | 22·2% (3·2–25·0) |
| Moderate sequelae in at least one domain | 5·0% (0·0–13·3) | 9·3% (0·0–21·8) | 6·7% (1·1–13·3) | 2·9% (0·0–8·3) | 5·5% (0·0–13·4) | 1·5% (0·0–12·7) | .. | 11·1% (0·0–27·3) | 5·8% (0·0–12·5) | .. | 22·8% (2·1–29·2) |
| Minor or mild sequelae in at least one domain | 10·0% (1·4–17·9) | .. | 10·0% (0·0–20·0) | 8·5% (1·4–12·5) | 13·9% (4·7–25·0) | 4·2% (2·6–10·9) | .. | 11·1% (8·0–19·1) | 12·5% (5·2–17·4) | 13·1% (4·1–31·7) | 11·1% (5·0–37·5) |
| Severe cognitive or learning difficulties | 17·3% (6·3–26·9) | 26·4% (22·2–30·0) | 11·4% (5·6–18·9) | 25·0% (17·9–40·7) | 7·0% (4·1–18·7) | .. | .. | 19·6% (5·9–37·8) | 36·4% (6·3–40·6) | .. | 10·7% (4·8–16·7) |
| Moderate cognitive or learning difficulties | 7·1% (0·0–12·5) | .. | .. | 6·9% (0·0–11·5) | 11·0% (5·6–13·9) | .. | .. | .. | 7·5% (4·3–10·0) | .. | 6·5% (4·8–8·3) |
| Mild cognitive or learning difficulties | 10·0% (0·7–15·0) | .. | 14·4% (0·0–15·8) | 2·4% (0·0–10·0) | 14·0% (7·4–22·7) | .. | .. | 13·2% (3·6–14·3) | 9·1% (3·0–15·0) | .. | 8·9% (8·3–9·5) |
| Severe cerebral palsy | 11·4% (7·4–24·0) | .. | 10·0% (2·7–11·4) | 24·0% (16·7–36·5) | 9·2% (4·1–12·1) | .. | .. | .. | .. | .. | .. |
| Moderate cerebral palsy | 2·4% (0·0–6·6) | .. | .. | 1·4% (0·0–4·3) | 5·5% (3·5–7·5) | .. | .. | .. | .. | .. | .. |
| Mild cerebral palsy | 1·5% (0·0–4·1) | .. | 1·8% (0·0–12·8) | 0·9% (0·0–1·6) | 4·1% (2·0–6·7) | .. | .. | .. | .. | .. | .. |
| Deaf or severe hearing loss | 4·9% (1·1–17·4) | 11·1% (4·1–19·4) | 0·6% (0·0–1·5) | .. | 1·8% (0·9–4·3) | .. | .. | 9·5% (5·6–17·4) | .. | 37·7% (21·4–60·2) | .. |
| Mild to moderate hearing loss | 10·4% (0·0–15·2) | 4·8% (0·0–21·4) | 6·5% (0·9–13·1) | .. | 0·3% (0–4·3) | .. | .. | 13·6% (11·1–16·7) | .. | 13·1% (5·4–17·9) | .. |
| Blind or severe visual loss | 2·4% (0·6–10·0) | 11·1% (5·6–12·5) | 4·5% (1·1–12·3) | .. | 1·9% (0·5–2·8) | .. | .. | .. | .. | .. | 22·2% (3·2–25·0) |
| Mild to moderate visual impairment | .. | .. | 14·5% (4·5–30·0) | .. | 0·7% (0·0–4·0) | .. | .. | .. | .. | .. | 33·3% (7·1–66·7) |
| Multiple impairments | 13·8% (8·0–33·3) | .. | .. | 20·5% (14·7–37·8) | 8·1% (3·7–10·2) | 12·4% (5·5–19·4) | .. | 22·6% (8·3–33·3) | .. | .. | .. |
Data are median (IQR). No data are given when the numbers were too few, domain was not assessed, or the impairment was graded.
Cerebral palsy was not defined and classified but motor and coordination impairments were reported.
Figure 2Random effect meta-analysis of the risk of development of one sequela by insult
Meta-regression analysis of the effect of key variables on the risk of sequelae
| OR (95% CI) | p value | OR (95% CI) | p value | ||
|---|---|---|---|---|---|
| Americas | 13 951 (68) | 1·00 | .. | 1·00 | .. |
| European | 6716 (59) | 1·03 (0·92–1·16) | 0·58 | 0·93 (0·67–1·30) | 0·68 |
| Western Pacific | 1187 (15) | 0·97 (0·85–1·12) | 0·72 | 0·86 (0·61–1·21) | 0·38 |
| Southeast Asia | 158 (5) | 0·90 (0·71–1·14) | 0·36 | 0·78 (0·52–1·18) | 0·24 |
| Africa | 115 (3) | 1·06 (0·80–1·39) | 0·70 | 0·93 (0·61–1·41) | 0·71 |
| East Mediterranean | 34 (1) | 0·85 (0·53–1·35) | 0·49 | 0·74 (0·42–1·29) | 0·28 |
| <1980 | 7452 (38) | 1·00 | .. | 1·00 | .. |
| 1980–89 | 6559 (48) | 0·94 (0·86–1·03) | 0·18 | 0·87 (0·54–1·42) | 0·59 |
| 1990–99 | 6108 (47) | 1·09 (1·00–1·19) | 0·06 | 0·97 (0·59–1·57) | 0·89 |
| ≥2000 | 2042 (19) | 0·94 (0·82–1·08) | 0·37 | 0·86 (0·52–1·41) | 0·55 |
| <12 | 1631 (29) | 0·96 (0·86–1·06) | 0·40 | 1·06 (0·90–1·24) | 0·49 |
| 12–35 | 8184 (52) | 1·01 (0·89–1·08) | 0·85 | 1·07 (0·93–1·24) | 0·33 |
| 36–60 | 1315 (18) | 0·92 (0·88–1·06) | 0·21 | 1·01 (0·87–1·18) | 0·88 |
| >60 | 10 002 (39) | 1·00 | .. | 1·00 | .. |
| Mixed (across the age ranges) | 1029 (15) | 1·12 (1·01–1·33) | 0·03 | 1·15 (0·96–1·38) | 0·13 |
| Prospective | 20 095 (124) | 1·00 | .. | 1·00 | .. |
| Retrospective | 2066 (29) | 1·06 (1·00–1·17) | 0·28 | 1·05 (0·94–1·18) | 0·39 |
Estimates compared to most prevalent group within the subgroup.
Multivariate regression approach (WHO region with the Americas as the baseline, data collection period with <1980 as the baseline, follow-up with >60 months as the baseline).